JP6363595B2 - 歯周炎および歯周炎に関連する疾患を処置または予防する方法 - Google Patents

歯周炎および歯周炎に関連する疾患を処置または予防する方法 Download PDF

Info

Publication number
JP6363595B2
JP6363595B2 JP2015518554A JP2015518554A JP6363595B2 JP 6363595 B2 JP6363595 B2 JP 6363595B2 JP 2015518554 A JP2015518554 A JP 2015518554A JP 2015518554 A JP2015518554 A JP 2015518554A JP 6363595 B2 JP6363595 B2 JP 6363595B2
Authority
JP
Japan
Prior art keywords
periodontitis
individual
porphyromonas gingivalis
cell
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015518554A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015523999A (ja
Inventor
ジョージ・ハジシェンガリス
ジョン・ディ・ランブリス
Original Assignee
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア, ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア filed Critical ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア
Publication of JP2015523999A publication Critical patent/JP2015523999A/ja
Application granted granted Critical
Publication of JP6363595B2 publication Critical patent/JP6363595B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/18—Dental and oral disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
JP2015518554A 2012-06-20 2013-06-19 歯周炎および歯周炎に関連する疾患を処置または予防する方法 Active JP6363595B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261662022P 2012-06-20 2012-06-20
US61/662,022 2012-06-20
US13/801,096 US9579360B2 (en) 2012-06-20 2013-03-13 Methods of treating or preventing periodontitis and diseases associated with periodontitis
US13/801,096 2013-03-13
PCT/US2013/046599 WO2013192319A1 (en) 2012-06-20 2013-06-19 Methods of treating or preventing periodontitis and diseases associated with periodontitis

Publications (2)

Publication Number Publication Date
JP2015523999A JP2015523999A (ja) 2015-08-20
JP6363595B2 true JP6363595B2 (ja) 2018-07-25

Family

ID=49769337

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015518554A Active JP6363595B2 (ja) 2012-06-20 2013-06-19 歯周炎および歯周炎に関連する疾患を処置または予防する方法

Country Status (8)

Country Link
US (2) US9579360B2 (enExample)
EP (1) EP2863949B1 (enExample)
JP (1) JP6363595B2 (enExample)
CN (1) CN104640567A (enExample)
AU (1) AU2013277217B2 (enExample)
CA (1) CA2877299C (enExample)
IN (1) IN2015DN00438A (enExample)
WO (1) WO2013192319A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2753636T (pt) * 2011-09-07 2020-01-21 Univ Pennsylvania Análogos de compstatina com propriedades farmacocinéticas melhoradas
US9579360B2 (en) * 2012-06-20 2017-02-28 The Trustees Of The University Of Pennsylvania Methods of treating or preventing periodontitis and diseases associated with periodontitis
EA201691727A1 (ru) 2014-02-25 2017-01-30 Ачиллион Фармасьютикалс, Инк. Фосфонатные соединения для лечения опосредованных комплементом нарушений
ES2895029T3 (es) 2014-06-12 2022-02-17 Ra Pharmaceuticals Inc Modulación de actividad del complemento
HUE056613T2 (hu) 2015-01-28 2022-02-28 Ra Pharmaceuticals Inc Komplementaktivitás modulátorai
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
WO2017035409A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
FI3359555T3 (fi) 2015-10-07 2024-03-20 Apellis Pharmaceuticals Inc Annostusohjeet
ES2941640T3 (es) 2015-12-16 2023-05-24 Ra Pharmaceuticals Inc Moduladores de la actividad del complemento
EP3551210A1 (en) 2016-12-07 2019-10-16 RA Pharmaceuticals, Inc. Modulators of complement activity
AU2018227849B2 (en) 2017-03-01 2022-04-28 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
CN111163767A (zh) 2017-08-02 2020-05-15 艾其林医药公司 治疗阵发性睡眠性血红蛋白尿症的治疗方案
CN111683672A (zh) 2017-12-04 2020-09-18 Ra制药公司 补体活性调节剂
WO2019118938A1 (en) 2017-12-15 2019-06-20 Apellis Pharmaceuticals, Inc. Dosing regimens and related compositions and methods
PL3645550T3 (pl) 2018-04-06 2022-04-04 The Trustees Of The University Of Pennsylvania Analogi kompstatyny o zwiększonej rozpuszczalności i ulepszonych właściwościach farmakokinetycznych
EP3847174A4 (en) 2018-09-06 2022-06-15 Achillion Pharmaceuticals, Inc. MORPHIC FORMS OF COMPLEMENT D FACTOR INHIBITORS
WO2020051532A2 (en) 2018-09-06 2020-03-12 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for the treatment of medical disorders
JP2022502500A (ja) 2018-09-25 2022-01-11 アキリオン ファーマシューティカルズ， インコーポレーテッド 補体因子ｄ阻害剤の形態
JP7471300B2 (ja) 2018-12-17 2024-04-19 アキリオン ファーマシューティカルズ， インコーポレーテッド 補体介在性疾患を治療するための的を絞った投与
CN113543796A (zh) 2019-03-08 2021-10-22 Ra制药公司 齐鲁考普作为深层组织穿透性c5抑制剂
EP3941462A4 (en) 2019-03-22 2023-04-05 Achillion Pharmaceuticals, Inc. PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT-MEDIED DISEASES
TW202102481A (zh) 2019-03-29 2021-01-16 美商Ｒａ製藥公司 補體調節劑和相關方法
BR112021017820A2 (pt) 2019-04-24 2022-02-08 Ra Pharmaceuticals Inc Composições e métodos para modulação da atividade de complemento
EP3980047B1 (en) 2019-06-04 2024-02-14 RA Pharmaceuticals, Inc. Inflammatory disease treatment with complement inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270365A (en) 1991-12-17 1993-12-14 Merck & Co., Inc. Prevention and treatment of periodontal disease with alendronate
US5627264A (en) * 1994-03-03 1997-05-06 Alexion Pharmaceuticals, Inc. Chimeric complement inhibitor proteins
JP2001294536A (ja) * 2000-04-12 2001-10-23 Sunstar Inc 歯周病予防・治療剤
US20050169921A1 (en) * 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
RS53599B1 (sr) * 2005-05-10 2015-02-27 Intermune, Inc. Piridon derivati za modulaciju stresom aktiviranog sistema proteinskih kinaza
WO2008097525A2 (en) * 2007-02-05 2008-08-14 Potentia Pharmaceuticals, Inc. Local complement inhibition for treatment of complement-mediated disorders
WO2010056399A1 (en) * 2008-11-17 2010-05-20 Incode Biopharmaceutics, Inc. Method and composition for modulating the immune system and various inflammatory conditions comprising complement depletors
CA2760839C (en) * 2009-05-01 2019-02-12 The Trustees Of The University Of Pennsylvania Modified compstatin with peptide backbone and c-terminal modifications
WO2010132954A1 (en) 2009-05-21 2010-11-25 Oral Health Australia Pty Ltd Method of treating periodontal disease by administering antagonists of par-2
US8642614B2 (en) * 2009-09-23 2014-02-04 The Regents Of The University Of Colorado, A Body Corporate Toll-like receptor modulators and uses thereof
WO2011091366A2 (en) 2010-01-22 2011-07-28 University Of Louisville Research Foundation, Inc. Methods of treating or preventing periodontitis and diseases associated with periodontitis
WO2011115225A1 (ja) * 2010-03-17 2011-09-22 国立大学法人 鹿児島大学 歯周病特異的ペプチド、並びにそれを用いた歯周病の治療および診断
US10039802B2 (en) * 2011-06-22 2018-08-07 Apellis Pharmaceuticals, Inc. Methods of treating chronic disorders with complement inhibitors
PT2753636T (pt) * 2011-09-07 2020-01-21 Univ Pennsylvania Análogos de compstatina com propriedades farmacocinéticas melhoradas
US9579360B2 (en) * 2012-06-20 2017-02-28 The Trustees Of The University Of Pennsylvania Methods of treating or preventing periodontitis and diseases associated with periodontitis

Also Published As

Publication number Publication date
CA2877299A1 (en) 2013-12-27
AU2013277217B2 (en) 2018-03-08
US20170202935A1 (en) 2017-07-20
IN2015DN00438A (enExample) 2015-06-19
US10668135B2 (en) 2020-06-02
CN104640567A (zh) 2015-05-20
AU2013277217A2 (en) 2015-01-22
CA2877299C (en) 2022-07-12
JP2015523999A (ja) 2015-08-20
EP2863949B1 (en) 2019-01-23
AU2013277217A1 (en) 2015-01-22
US20130344082A1 (en) 2013-12-26
US9579360B2 (en) 2017-02-28
EP2863949A4 (en) 2016-03-02
EP2863949A1 (en) 2015-04-29
WO2013192319A1 (en) 2013-12-27

Similar Documents

Publication Publication Date Title
JP6363595B2 (ja) 歯周炎および歯周炎に関連する疾患を処置または予防する方法
Maekawa et al. Genetic and intervention studies implicating complement C3 as a major target for the treatment of periodontitis
Hajishengallis et al. Complement-dependent mechanisms and interventions in periodontal disease
Silva et al. Primary immunodeficiencies reveal the essential role of tissue neutrophils in periodontitis
US20160084820A1 (en) Methods of treating or preventing periodontitis and diseases associated with periodontitis
Marcotte et al. Oral microbial ecology and the role of salivary immunoglobulin A
Graves et al. The use of rodent models to investigate host–bacteria interactions related to periodontal diseases
Hajishengallis et al. Complement inhibition in pre-clinical models of periodontitis and prospects for clinical application
Schenkein et al. Cytokines and inflammatory factors regulating immunoglobulin production in aggressive periodontitis.
US20140302027A1 (en) Methods of treating periodontal inflammation and periodontal bone loss
Perayil et al. Comparison of the efficacy of subgingival irrigation with 2% povidone-iodine and tetracycline HCl in subjects with chronic moderate periodontitis: A clinico microbiological study
WO2015175512A1 (en) Compositions and methods of regulating bone resorption
Dommisch et al. Periodontitis (Chronic Periodontitis, Necrotizing Ulcerative Periodontitis, and Aggressive Periodontitis)
Hutomo et al. The role of the immune response in the development of pneumonia arising from oral periodontitis: a literature review
WO2010132954A1 (en) Method of treating periodontal disease by administering antagonists of par-2
Toda et al. The Mechanism of Inflammation Caused by Oral Infection with Fusobacterium nucleatum in Periodontal Tissue
Zambrano Pacheco et al. Use of Probiotics as Adjuncts in Non-Surgical Periodontal Therapy: A Literature Review
Mooney Characterizing A20 function in periodontal tissue homeostasis
Ergun Oral Aspects of Sjögren’s Syndrome
Zenobia Oral Polymicrobial Communities in Health and Disease
Ergun Oral Aspects of Sjogren’s Syndrome
Rittling Evaluation of αlphav integrin role in mouse model induced periapical periodontitis
Pacios Pujadó Cellular mechanisms that affect periodontal destruction induced by bacteria infection in diabetic and non diabetic rats
Gaitán Fonseca et al. Lifestyle and relationship with periodontal disease
Allahem Evaluation of αLphav Integrin Role in Mouse

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150220

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160602

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170404

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170704

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171017

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180315

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180605

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180628

R150 Certificate of patent or registration of utility model

Ref document number: 6363595

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250